Physician profile
Joseph Johnson
NPI 1760442834
$3,624.68
in general payments reported to CMS, 2019-2025
26 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $412 · 2022: $184 · 2023: $105 · 2024: $139 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,611 · Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,610.66 |
| Food and Beverage | $462.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,930.90 | 2022-2025 | Pangea |
| Amgen INC. | $191.53 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $188.97 | 2019-2020 | |
| Depuy Synthes Sales INC. | $159.33 | 2019 | |
| Supernus Pharmaceuticals, INC. | $152.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $114.28 | 2019-2020 | |
| Glaxosmithkline, LLC. | $103.35 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.34 | 2019-2024 | Jardiance, Tradjenta |
| Novo Nordisk INC | $82.60 | 2019-2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $79.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $53.15 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $52.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.34 | 2019-2020 | |
| Abbvie INC. | $50.58 | 2019-2024 | |
| Astellas Pharma US INC | $50.53 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $50.00 | 2022 | |
| Pfizer INC. | $48.60 | 2019-2024 | |
| Dexcom, INC. | $38.69 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $28.31 | 2024-2025 | Cologuard Collection Kit |
| Upsher-Smith Laboratories LLC | $20.37 | 2019 | |
| Ibsa Pharma INC. | $19.70 | 2023 | Tirosint, Licart |
| Eisai INC. | $18.22 | 2020 | |
| Allergan, INC. | $13.88 | 2020 | |
| Lilly USA, LLC | $13.84 | 2019 | |
| Sanofi Pasteur INC. | $13.65 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.